Indication (pathologie):
Carcinome hépatocellulaire
Identifiant SNOMED-CT:
SCTID 25370001
Etudes cliniques
-
L’enfant face au cancer d’un parent: une étude randomisée évaluant l’efficacité d’une intervention psychologique destinée à soutenir la parentalitéRecrutement: Ouvert
-
A phase III study of pembrolizumab versus best supportive care as second-line therapy in subjects with previously systemically treated advaced hepatocellular carcinomaPhase de l'étude: Phase IIIRecrutement: Fermé
-
IBD Cancer and Serious infections in Europe : I-CARE. A multicenter, prospective, observational cohort studyIndication (pathologie):CrohnIdentifiant SNOMED-CT:SCTID 34000006Indication (pathologie):Rectocolite ulcéro-hémorragique (RCUH)Identifiant SNOMED-CT:SCTID 64766004Phase de l'étude: Phase IVRecrutement: Ouvert
-
Phase 3b randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCGIndication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 254900004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase 2 randomized open-label study of oral ODM-201 vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancerIndication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 254900004Phase de l'étude: Phase IIRecrutement: Ouvert
-
A randomized, double-blind, placebo controlled phase3 study of ODM 201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancerIndication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 427492003Indication (pathologie):Metastatic hormone sensitive prostate cancerPhase de l'étude: Phase IIIRecrutement: Fermé
-
A phase 3, multinational, randomised, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (INLYTA®) versus sunitinib (SUTENT®) monotherapy in the first-line treatment of patients with advanced renal cell carcinomaIndication (pathologie):Carcinome rénalIdentifiant SNOMED-CT:SCTID 702391001Phase de l'étude: Phase IIIRecrutement: Fermé
-
A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy (Javelin Bladder 100)Indication (pathologie):Cancer urothélialIdentifiant SNOMED-CT:SCTID 27090000Indication (pathologie):Cancer métastatiqueIdentifiant SNOMED-CT:SCTID 128462008Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A retrospective, international, multicentre study to describe the duration of routine treatment with abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC) patients without prior chemotherapyIndication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 427492003Indication (pathologie):Cancer de la prostate métastatique résistant à la castration (mCRPC)Identifiant SNOMED-CT:SCTID 128462008Recrutement: Ouvert
-
Randomized multicenters phase 3 trial comparing enzalutamide vs a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE IIIIndication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 427492003Indication (pathologie):Cancer de la prostate métastatique résistant à la castration (mCRPC)Identifiant SNOMED-CT:SCTID 128462008Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase 3 randomized, placebo-controlled double-blind study of JNJ-56021927 in combination with abiraterone acetate and prednisone Versus abiraterone acetate and prednisone in subjects with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)Indication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 427492003Indication (pathologie):Cancer de la prostate métastatique résistant à la castration (mCRPC)Identifiant SNOMED-CT:SCTID 128462008Phase de l'étude: Phase IIIRecrutement: Fermé
-
Etude de la valeur ajoutée des variations génétiques (SNPs) dans la prédiction de la réponse thérapeutique et la toxicité de l'hormonothérapieIndication (pathologie):Cancer prostateIdentifiant SNOMED-CT:SCTID 427492003Phase de l'étude: Phase IIIRecrutement: Fermé
-
PROSPER: A multinational, phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of enzalutamide in patients with nonmetastatic castration-resistant prostate cancerIndication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 427492003Indication (pathologie):Cancer prostate résistant à la castration non métastatique(CRPC)Phase de l'étude: Phase IIIRecrutement: Fermé
-
A randomised, double blind, multicenter, parallel-group, phase 3 study to evaluate efficacy and safety of DCVAC/Pca versus placebo in men with metastatic castration resistant prostate cancer eligible for 1st line chemotherapyIndication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 427492003Indication (pathologie):Cancer de la prostate métastatique résistant à la castration (mCRPC)Identifiant SNOMED-CT:SCTID 128462008Phase de l'étude: Phase IIIRecrutement: Fermé
-
A multicenter, single-arm, open-label, post-marketing safety study to evaluate the risk of seizure among subjects with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide who are at potential increased risk of seizureIndication (pathologie):Cancer de la prostate résistant à la castrationIdentifiant SNOMED-CT:SCTID 427492003Indication (pathologie):Cancer de la prostate métastatique résistant à la castration (mCRPC)Identifiant SNOMED-CT:SCTID 128462008Phase de l'étude: Phase IVRecrutement: Fermé
-
A prospective observational safety study in patients with advanced prostate cancer treated with FIRMAGON® (degarelix) or a GnRH agonistIndication (pathologie):Cancer de la prostateIdentifiant SNOMED-CT:SCTID 254900004Phase de l'étude: Phase IVRecrutement: Fermé
-
A phase 3, open label, randomised, multi-centre, international study of MEDI4736, versus standard of care in patients with locally advanced or metastatic non-small cell lung cancer (stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen and do not have known EGFR TK activating mutations or ALK rearrangements (ARCTIC)Indication (pathologie):Cancer du poumon à grandes cellulesIdentifiant SNOMED-CT:SCTID: 254637007Phase de l'étude: Phase IIIRecrutement: Fermé
-
A european prospective observational study assessing the effectiveness and outcomes associated with enzalutamide treatment in patients with metastatic castration resistant prostate cancer (mCRPC). PremiseIndication (pathologie):Cancer de la prostate résistant à la castrationIdentifiant SNOMED-CT:SCTID: 427492003Recrutement: Fermé
-
Trabectdin for recurrent grade II or III meningioma : a randomized phase II study of the EORTC brain tumor groupIndication (pathologie):MéningiomeIdentifiant SNOMED-CT:SCTID: 19453003Phase de l'étude: Phase IIRecrutement: Fermé
-
A randomised, double-blind, parallel group, placebo-controlled multicentre phase 3 study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OLYMPIA Study)Indication (pathologie):Mutation du cancer du seinIdentifiant SNOMED-CT:SCTID: 143691000119102Indication (pathologie):Récepteur 2 du facteur de croissance épidermique humain (HER2)Identifiant SNOMED-CT:SCTID: 427685000Phase de l'étude: Phase IIIRecrutement: Fermé